Skip to main content
Premium Trial:

Request an Annual Quote

Jim Lindelien, Roland Luethy, Steve McPhail, Donald Holzworth

Premium

TimeLogic founder Jim Lindelien is leaving the company “to pursue new opportunities,” according to a company statement. Lindelien, who started the company in 1994 and engineered its DeCypher accelerated bioinformatics technology, most recently held the position of CTO at TimeLogic. The company's primary technology development duties will now be the responsibility of Roland Luethy, senior bioinformatics research scientist, who joined the company in November. Prior to joining TimeLogic, Luethy served as a research scientist at Amgen from 1993.

Microarray analysis firm Expression Analysis (EA) has tapped Steve McPhail as its new CEO. McPhail joins EA from medical device manufacturer ArgoMed, where he served as executive vice president and COO. Prior to joining ArgoMed, McPhail held senior-level sales, marketing and business development positions for Xanthon, TriPath Imaging, Dynex Technologies, and Abbott Laboratories. He replaces Donald Holzworth, president and CEO of Analytical Sciences, who has acted as EA’s interim CEO since Sept. 2001 when ASI began incubating the company.

 

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more